0000000000587328

AUTHOR

Charlotte Ling

0000-0003-0587-7154

showing 2 related works from this author

Epigenetic differences arise during the lifetime of monozygotic twins.

2005

Monozygous twins share a common genotype. However, most monozygotic twin pairs are not identical; several types of phenotypic discordance may be observed, such as differences in susceptibilities to disease and a wide range of anthropomorphic features. There are several possible explanations for these observations, but one is the existence of epigenetic differences. To address this issue, we examined the global and locus-specific differences in DNA methylation and histone acetylation of a large cohort of monozygotic twins. We found that, although twins are epigenetically indistinguishable during the early years of life, older monozygous twins exhibited remarkable differences in their overall…

AdultMalemedicine.medical_specialtyADNRestriction MappingTwinsMonozygotic twinX-inactivationEpigenesis GeneticHistonesX Chromosome InactivationSurveys and QuestionnairesGenotypemedicineHumansEpigeneticsOligonucleotide Array Sequence AnalysisGeneticsAnalysis of VarianceMultidisciplinarybiologyReverse Transcriptase Polymerase Chain ReactionElectrophoresis CapillaryGene Expression Regulation DevelopmentalAcetylationNucleic acid amplification techniqueDNASequence Analysis DNATwins MonozygoticDNA MethylationExpressió gènicaFenotipHistonePhenotypeSpainDNA methylationbiology.protein5-MethylcytosineCommentaryMedical geneticsBessonsFemaleGene expressionNucleic Acid Amplification TechniquesProceedings of the National Academy of Sciences of the United States of America
researchProduct

Epigenetic markers associated with metformin response and intolerance in drug-naïve patients with type 2 diabetes

2020

Metformin is the first-line pharmacotherapy for managing type 2 diabetes (T2D). However, many patients with T2D do not respond to or tolerate metformin well. Currently, there are no phenotypes that successfully predict glycemic response to, or tolerance of, metformin. We explored whether blood-based epigenetic markers could discriminate metformin response and tolerance by analyzing genome-wide DNA methylation in drug-naïve patients with T2D at the time of their diagnosis. DNA methylation of 11 and 4 sites differed between glycemic responders/nonresponders and metformin-tolerant/intolerant patients, respectively, in discovery and replication cohorts. Greater methylation at these sites associ…

Blood Glucose0301 basic medicineOncologymedicine.medical_specialtyendocrine system diseases030209 endocrinology & metabolismType 2 diabetesEpigenesis Genetic03 medical and health sciences0302 clinical medicineInternal medicineDiabetes mellitusmedicineHumansHypoglycemic AgentsEpigeneticsGlycemicbusiness.industrynutritional and metabolic diseasesGeneral MedicineOdds ratioDNA Methylationmedicine.diseaseMetformin3. Good healthMetforminDrug-naïve030104 developmental biologyDiabetes Mellitus Type 2Pharmaceutical PreparationsDNA methylationbusinessmedicine.drugScience Translational Medicine
researchProduct